DUB inhibition can effectively treat cancer by inactivating P53 and BAP1 through inhibiting the expression of SLC7A11 or upregulating either OTUB1 or CD44 to stabilize the SLC7A11 protein, inducing proteasome inhibition and apoptosis [53]. Here, SLC7A11 is linked to cancer.